Kornimate/medical-research-clean huggingface dataset:
the impact of the scn9a gene polymorphism on postoperative pain

Conditions: Pain, Postoperative; Pregnancy

Summary: the purpose of this study to determine the association between postoperative pain after cesarean section and several single nucleotide polymorphisms in scn9a sodium channels gene.

scn9a gene encodes an alpha subunit of the voltage-gated sodium channel (nav1.7) and polymorphisms of this gene are associated with severe pain disorders. the impact of the polymorphisms in scn9a on postoperative pain and opioid consumption after cesarean section is unclear.

Eligibility criteria:
inclusion criteria: * the women aged 18 to 45, * in 36 to 40 weeks of pregnancy * undergoing cesarean section exclusion criteria: * history of chronic pain or pain disorders * psychiatric diseases * diabetes mellitus * severe cardiovascular, kidney or liver diseases * alcohol or drug abuse * heavy smoker * unable to use the patient controlled analgesia (pca) pump

Keywords: nav1.7 voltage-gated sodium channel pain, postoperative cesarean section
dkutting balloon versus chocolate balloon to treat femoral and popliteal artery stenosis

Conditions: Femoral Artery Stenosis; Popliteal Artery Stenosis

Summary: a multicenter, prospective, randomized controlled trial to evaluate the efficacy and safety of dkutting balloon versus chocolate balloon in the treatment of femoral and popliteal artery stenosis

this is a prospective, multi-center, randomized controlled, open-label, noninferior study to evaluate achievement of optimal pta dilatation. a total of 188 patients will be enrolled from 14 sites in china. all patients enrolled will be assigned to the test group (dkutting ll balloon, n=94) and the control group (chocolate balloon, n=94) with randomized allocation ratio of 1:1. primary endpoint is percentage of pta cases in which \<30% diameter stenosis without a flow limiting dissection is achieved. a 30-day after procedure follow-up will be conducted for all 188 patients.

Eligibility criteria:
inclusion criteria: * 18-80 year-old male \& non-pregnant female * patients with arteriosclerosis obliterans of lower extremities, including stenosis or osculation in femoropopliteal artery. * rutherford clinical category-becker class: 2 to 5 * patients understand the purpose of the study, will voluntarily participate in the study and sign informed consent. patients are willing to undergo clinical follow-up as required by this study. * digital subtraction angiography (dsa) shows femoropopliteal artery stenosis above 70%, appropriate for treatment with balloon angioplasty * reference vessel diameter from 2.5 to 7mm; total length of lesion is less than 200mm; total length of osculation lesion is less than 100mm * only one target lesion needs to be treated. treatment of non-target lesion, if any, must be completed prior to treatment of target lesion and must be deemed a clinical angiographic success as visually assessed by the physician. the number non-target lesions are limited to maximum 3. exclusion criteria: * acute or sub-acute thrombosis exist in target lesion * severe calcified lesion (pacss grading 4) * guidewire cannot cross target lesion * amputation planned within 30 days * in-stent restenosis * flow-limiting dissection (nhlbi grading: d-f) occurred in target lesion by pre-dilation * no other lumen-reduction devices (such as: cutting balloon, dual-wire balloon, hawk, elca etc.) are treated before or after test/control group treatment. * before test/control group treatment, target lesion was expanded by antegrade dissection re-entry (adr) technique. * patient who cannot accept anticoagulant or antiplatelet therapy * aware of patient allergic to heparin, contrast, aspirin and clopidogrel, anesthetics * patients who have not completed clinical trials of other drugs or devices * patients with poor compliance and unable to complete the study, which is identified by investigator.

Keywords: pta scoring balloon optimal balloon angioplasty
managing dysfunctional breathing and exercise-induced laryngeal obstruction in adolescent athletes

Conditions: Exercise Induced Laryngeal Obstruction (EILO)

Summary: this study aimed to assess if a multidimensional individually tailored intervention, including norwegian psychomotor physiotherapy (npmp), elements of cognitive behavioural therapy and a rehabilitation plan, helped reduce inspiratory distress and dysfunctional breathing in adolescent athletes with eilo. a mixed methods design, which combined qualitative and quantitative research, was used. data, including subjective experiences of respiratory distress, findings from npmp body examinations and objective measurements of lung function and aerobic capacity were gathered before and after a five month intervention involving 18 participants.


Eligibility criteria:
inclusion criteria: * adolescent athletes with symptoms of eilo * referred to norwegian psychomotor physiotherapy exclusion criteria: * other respiratory symptoms * additional diagnosis

Keywords: eilo physiotherapy intervention dysfunctional breathing adolescent athletes diaphragmatic breathing postural alignment
individual vs cohort long distance advising for mental care for congenital cataract guardians

Conditions: Cataract

Summary: nowadays, doctors put mental health at a prior place and pay more attention to the psychological problems of ill kids' parents. in our research, we try to find a new modern and efficient psychological counseling mode to improve the mentality of parents and relieve their anxiety and depression. we divide guardians of parents into two groups .one group is given the traditional follow-up by regular phone call every month. the other is in a wechat group. a doctor send the useful information about kids care and answer questions of parents at regular time every month. the self-rating anxiety scale (sas) and self-rating depression scale (sds) scores of parents are marked before and after the long follow up.

congenital cataract (cc) is the leading cause of reversible blindness during childhood, which appears at birth or during the first decade of life. nowadays, doctors put mental health at a prior place and pay more attention to the psychological problems of ill kids' parents. in our research, we try to find a new modern and efficient psychological counseling mode to improve the mentality of parents and relieve their anxiety and depression. we divide guardians of parents into two groups .one group is given the traditional follow-up by regular phone call every month. the other is in a wechat group. a doctor send the useful information about kids care and answer questions of parents at regular time every month. the self-rating anxiety scale (sas) and self-rating depression scale (sds) scores of parents are marked before and after the long follow up.

Eligibility criteria:
inclusion criteria: the guardians of kids who had a surgery for congenital cataract recently exclusion criteria: have other major life hit was diagnosed of anxiety and depression before

Keywords: congenital cataract anxiety guardian
medical abortion for emergency contraception failure

Conditions: Emergency Contraception; Abortion, Induced

Summary: the purpose of this study is to compare the efficacy, safety and acceptability of pre-treatment with mifepristone and misoprostol compared to misoprostol alone in the medical termination of pregnancy by mifepristone ec failure.

women usually request an abortion when they have experienced an emergency contraception (ec) failure; this population represents 13% of all early pregnancy terminations in china. many women would prefer to choose a medical abortion in order to avoid anesthesia, over a surgical operation. however, medical termination of a pregnancy after mifepristone ec failure has not been studied although it has already been extensively practiced by empirical means in china. there is no clarification in literature as to whether mifepristone is still effective in medical abortion with its previous failure experience in ec. this randomized study was aimed to compare the efficacy, safety and acceptability of pre-treatment with mifepristone and misoprostol compared to misoprostol alone in the medical termination of pregnancy by mifepristone ec failure.

Eligibility criteria:
inclusion criteria: * participants included in the study were women aged 16 years or older * with good general health, * experiencing a mifepristone emergency contraception failure, * presenting an intrauterine singleton pregnancy confirmed by pelvic ultrasound scan, with a crown-rump length compatible within 56 days of gestation at the enrolled day, and * seeking a medical abortion for unwanted pregnancy. * women who had a threatened abortion or a failure pregnancy were also included. * participants were required to sign an informed consent form before enrolment, willing to comply with the schedule of follow-up visits and willing to undergo surgical aspiration if indicated. exclusion criteria: * the exclusion criteria included suspected or proven ectopic pregnancy, * allergy or contraindications for mifepristone (chronic systemic corticosteroid therapy, adrenal insufficiency) or misoprostol (hypertension, mitral stenosis, severe asthma, glaucoma, sickle cell anemia and hypotension), * history or evidence of thromboembolism, cardiovascular disease or liver disease, hemoglobin ≤ 90 g/l, heavy smoking (more than 10 per day), * presence of an intrauterine device, and breastfeeding. * other exclusion criteria included participants who had ec failure because incorrect use, for example, having further unprotected intercourse after ec.

Keywords: medical abortion emergency contraception mifepristone
endothelial facilitation in alzheimer's disease

Conditions: Alzheimer's Disease

Summary: purpose of the study: patients with mild alzheimer's disease will be given three different drugs over a 4-month period to try to increase the blood flow to their brains, and improve blood vessel and brain function. each drug can help to open the blood vessels in the brain, and together they may be more effective than each drug alone. the hypothesis is that small blood vessels secrete substances that maintain the integrity of the brain, and may prevent loss of nerve cells leading to alzheimer's disease


Eligibility criteria:
inclusion criteria: * subjects must have mild alzheimer's disease or mild cognitive impairment (mci); * age between 55-85; * mini mental status exam (mmse) between 15-26; * a caregiver who can provide information, and bring patient to the sessions; * no known allergies to any of the medications to be used; * normal renal function; willingness of patient and spouse/responsible caregiver to participate. exclusion criteria: * significant psychiatric disorder; * stroke; current use of any of the test medications (e.g., statin, l-arginine, kuvan); * phenylketonuria (pku) ; * elevated serum phenylalanine level (\>10 mg/dl); * allergy to any of the medications; current active malignancy; * renal insufficiency (elevated creatinine above 1.3mg/dl); * abnormal liver function (alanine aminotransferase (alt) or aspartate transaminase (ast) 2x normal); * other serious disease including coronary insufficiency or congestive heart failure, carotid stenosis greater than 50%, active peptic ulcer, urinary tract or other active infection, cancer (except skin cancer, or 5 years inactive breast or prostate cancer )etc.; * pregnancy; or * inability to come to umass for follow-up. subjects may continue to take anticholinesterase drugs for alzheimer's disease (aricept, exelon, razadyne) and/or namenda, if they have been on the drug(s) for at least 3 months. subjects on levodopa and male subjects taking drugs for erectile dysfunction (viagra, cialis, levitra) are cautioned regarding hypotension.

Keywords: early alzheimer mild cognitive impairment drug treatment cerebral blood flow endothelial facilitation cognitive improvement
improving arteriovenous fistula patency

Conditions: Thrombosis

Summary: all vascular access guidelines recommend monitoring and surveillance protocols to prevent vascular access complications in hemodialysis units. however, in the case of second generation screening techniques which determine access blood flow measurement (qa), there is a huge controversy about it´s efficiency. although multiple observational studies find a decrease in the thrombosis rate and an increased primary assisted patency survival related to the use of these techniques, a recently published meta-analysis find contradictory results in the randomized controlled trials, affirming that the measurement of qa is useless in grafts and questionable in native arteriovenous fistulae (avf). we have designed a multicenter, prospective, open label, controlled, randomized trial, to prove the usefulness of the qa measurement using two complementary second generation techniques, doppler ultrasound and transonic dilution method, compared to the classical monitoring and surveillance methods. the primary endpoint will be a reduction in the thrombosis rate with an increased assisted primary patency survival, and a cost effectiveness economic analysis. as secondary endpoints we will analyze the impact over non-assisted primary patency survival and secondary patency survival.

definition: multicenter, prospective, open label, controlled, randomized trial, to prove the usefulness of the qa measurement using two complementary second generation techniques, doppler ultrasound and transonic dilution method, compared to the classical monitoring and surveillance methods. for patient registries: clinical data repository (cdr) paper notebook will contain all baseline patient characteristics and the information related to vascular access. these data will be collected by the different investigators and reviewed and included in data base by the study´s monitor. this information will be included in a centralized computer database (spss 15.0 computer system) and encoded in order to preserve patients´ confidentiality.

Eligibility criteria:
inclusion criteria: * informed consent signature. * age between 18 and 95 years old. * functioning native avf. * patients with end stage renal disease (esrd) undergoing hemodialysis program for at least three months. exclusion criteria: * coagulopathy or hemoglobinopathy of any cause. * hospitalization of any cause in the previous month. * va related complications or dysfunction in the previous three months.

Keywords: thrombosis arteriovenous fistulae hemodialysis doppler ultrasound vascular access blood flow surveillance
behavioral comparison of three different graft materials to increase soft tissue thickness around dental implants.

Conditions: Soft Tissue Atrophy; Mucogingival Deformity on Edentulous Ridge; Edentulous Alveolar Ridge

Summary: the purpose of the study is to compare soft tissue volume changes in terms of volume gain and stability around dental implants and proms in cases where a sub-epithelial connective tissue graft (sctg) from the palate, porcine collagen matrix (cm) or porcine acellular dermal matrix (padm) is used after 3 and 15 months after implant placement.


Eligibility criteria:
inclusion criteria: patients referred to department of periodontology (cuo) in need of a single implant and need of soft tissue augmentation such as buccal defects, thin biotype, lack of keratinized tissue and aesthetic compromised situation. * the patient must be ≥18 years and able to understand the nature of the proposed surgery and must sign an informed consent. * the implant must be located between 2 fixed reference points (i.e. clinical crowns). * anterior and premolar teeth (from premolar to premolar). * enough crestal bone width to leave a minimum thickness of 2mm at the buccal bone plate when placing the implant. * palate must have ≥2mm of thickness at premolar area. * full mouth plaque and bleeding score \<20%. exclusion criteria: * pregnant or lactation. * active periodontal disease. * previous soft tissue augmentation in the area. * need of guided bone regeneration (gbr) during or after the placement of the implant. * heavy smokers (\> 10 cigarettes per day). * local or systemic conditions that would interfere with routine periodontal therapy (non-controlled diabetes mellitus, cancer, hiv, chronic high dose steroid therapy, bone metabolic diseases, radiation, immunosuppressive disorders, liver function disorder, immunosuppressant disease, autoimmune disease). * allergy to non-steroidal anti-inflammatory drugs. * patients taking medications that cause gingival enlargement.

Keywords: soft tissue graft acellular dermal graft collagen matrix
long-term safety & efficacy of apitegromab in patients with sma who completed previous trials of apitegromab

Conditions: Spinal Muscular Atrophy; Spinal Muscular Atrophy Type 3; Spinal Muscular Atrophy Type 2; SMA; Neuromuscular Diseases; Muscular Atrophy; Atrophy; Muscular Atrophy, Spinal; Neuromuscular Manifestations; Anti-myostatin

Summary: the onyx study is an open-label, multicenter, extension study that will evaluate the long-term safety and efficacy of apitegromab in patients with type 2 and type 3 sma who have completed topaz or sapphire.


Eligibility criteria:
inclusion criteria: * patients have completed the phase 2 topaz (study srk-015-002) trial or the phase 3 sapphire (study srk-015-003) trial. (for topaz, completed is defined as completion of visit ec14 in extension period c or participating in topaz at the time the trial is ended. for sapphire, completed is defined as completion of visit 14 or participating in sapphire at the time the trial is ended) * estimated life expectancy \>2 years from the baseline visit (day 1) * able to receive study drug infusions and provide blood samples through the use of a peripheral iv or a long-term iv access device that the patient has placed for reasons independent from the trial * able to adhere to the requirements of the protocol, including travel to the trial site and completing all trial procedures and trial visits * females of childbearing potential must have a negative pregnancy test at the baseline visit and agree to use at least 1 highly effective method of contraception throughout the trial and for 20 weeks after the last dose of apitegromab exclusion criteria: * patient permanently discontinued study treatment during the feeder trial (i.e., topaz or sapphire) * nutritional status that was not stable over the past 6 months and is not anticipated to be stable throughout the trial or medical necessity for a gastric/nasogastric feeding tube, where the majority of feeds are given by this route, as assessed by the investigator * patient is currently enrolled in any investigational drug trial other than topaz or sapphire * prior history of severe hypersensitivity reaction or intolerance to smn-targeted therapies * prior history of severe hypersensitivity reaction or intolerance to apitegromab * use of chronic daytime noninvasive ventilatory support for \>16 hours daily in the 2 weeks before dosing, or anticipated to regularly receive such daytime ventilator support chronically throughout the trial * any acute or comorbid condition interfering with the well-being of the patient at the patient's last visit in topaz or sapphire, (including active systemic infection, the need for acute treatment, or inpatient observation due to any reason). after resolution of the condition, the patient can be enrolled in the trial if they meet all the other eligibility criteria. * pregnant or breastfeeding * any other condition or clinically significant laboratory result or ecg value that, in the opinion of the investigator, may compromise safety or compliance, would preclude the patient from successful completion of the trial, or interfere with the interpretation of the results
feasibility of the use of weighted blankets to improve sleep among patients with hematological malignancies

Conditions: Hematological Malignancies

Summary: the goal of this clinical research study is to learn about the effects of weighted blankets on sleep quality in patients with blood cancers. weighted blankets are heavier blankets that contain inner weight beads. the deep pressure stimulation induced by these blankets can have a calming effect.

primary objective: to determine the feasibility of using weighted blankets to improve sleep disturbances (sd) for patients with hematological malignancies in an outpatient setting. secondary objectives: to explore if weighted blanket use improves sleep as assessed by the esas sleep question. a positive response is defined by at least a one-point reduction in esas sleep between baseline and day 7 +/-2 days. to explore if weighted blanket use during a 14-day period improves insomnia severity index (isi) score. to explore the response rate in anxiety, where response is defined as a minimum of one-point change in the esas anxiety score, between baseline and day 7 +/-2 days after the use of weighted blankets. to explore if patients are satisfied with the use of weighted blankets as determined by a positive response to at least 2 of the 5 patient satisfaction questions. to assess safety using nci ctcae v5

Eligibility criteria:
inclusion criteria: 1. outpatient at md anderson cancer center 2. adult patients ≥ 18 years 3. diagnosis of hematological malignancy 4. esas sleep\&gt;/=4 5. performance status as measured by eastern cooperative oncology practice group (ecog) score of 2 or below exclusion criteria: 1. platelet count of 25 or below 2. history of seizures/intracranial metastasis/ sleep apnea/restless leg syndrome/paralysis 3. weight less than 150 lbs. 4. attending physician assessment of prognosis with expected life expectancy of \&lt;1 month 5. patients who are unable to tolerate their blankets/sheets in the night due to medical conditions such as pain, peripheral neuropathy, night sweats, hot flashes etc. 6. patients with difficulty breathing, disorders of poor circulation, fragile skin, rash, or open wounds, or by those who are claustrophobic or cleithrophobic. 7. prior use of weighted blankets within the past 1-year
lumbar spine manipulation versus pharmacological therapy in young women with primary dysmenorrhea

Conditions: Women With Primary Dysmenorrhea

Summary: many treatments like acupuncture, manipulative therapy and pharmacological therapy have been proposed to alleviate symptoms associated with dysmenorrhea. however, no study has previously compared lumbar spine manipulation to pharmacological therapy in the treatment of primary dysmenorrhea.


Eligibility criteria:
inclusion criteria: * presented with persistent primary dysmenorrhea lasting for three or more consecutive menstrual periods * presented menstrual cycles no longer than 35 days exclusion criteria: * presented any other gynecological pathologies * systemic diseases * previous surgical interventions for gynecological complaints * depression * were receiving any other treatment for primary dysmenorrhea.
evaluation of functional status, physical activity and quality of life in patients with rotator cuff syndrome

Conditions: Rotator Cuff Syndrome

Summary: pain is one of the most important factors affecting the quality of life. the quality of life of patients with pain and restricted shoulder movements can be affected in patients with rotator cuff syndrome (rcs).

the aim of our study is to examine the effect of the pain on functional status, quality of life and physical activity levels in daily life activities of rcs patients.

Eligibility criteria:
inclusion criteria: * patients presenting with shoulder pain problems and diagnosed with rcs. * individuals between the ages of 19-64 were included in the study. exclusion criteria: * those who have mental disability at the level of understanding the test and preventing interviews. * those with any chronic problems (such as cancer, kidney failure) * those who receive special medical treatment (steroid therapy, chemotherapy, insulin use.) * those who had a pregnancy status were excluded from the study.

Keywords: pain physical activity rotator cuff syndrome quality of life